Chemotherapy kills cancer by damaging cells during the process of division, either by wrecking their DNA or by disrupting the molecular machinery they need to copy themselves. Because cancer cells divide more frequently and more recklessly than most healthy cells, they’re disproportionately caught in the crossfire. But chemo isn’t a single weapon. It’s a collection of drugs that attack different stages of cell division through different mechanisms, and understanding those mechanisms explains both why chemo works and why it causes the side effects it does.
Why Cancer Cells Are Vulnerable
Every cell in your body follows a cycle: it grows, copies its DNA, and splits into two new cells. Normal cells do this in an orderly way, stopping when they receive signals that enough cells are present or when growth factors run low. They can enter a resting state and stay there indefinitely. Cancer cells ignore those stop signals. They proliferate continuously and without regulation, which is the fundamental abnormality that makes them dangerous.
This relentless division is also their weakness. Most chemotherapy drugs target cells in the active process of dividing. Since cancer cells spend more time dividing than most normal cells, they’re more likely to be hit. It’s not that chemo recognizes cancer. It’s that cancer puts itself in harm’s way more often.
Damaging the DNA Directly
One major class of chemo drugs works by physically damaging the DNA inside cancer cells so it can no longer be read or copied. Alkylating agents, one of the oldest types of chemo, attach chemical groups to the DNA strands and create abnormal links between them, called cross-links. These cross-links prevent the two strands of DNA from separating during replication. The cell tries to divide, finds its genetic instructions garbled, and triggers its own self-destruct program.
Another approach targets the enzymes that help DNA unwind. Before a cell can copy its DNA, it needs to relieve the tension in the tightly coiled double helix. Specific enzymes temporarily cut one or both strands, let the DNA relax, then rejoin the cut. Certain chemo drugs trap these enzymes mid-cut, leaving permanent breaks in the DNA. The cell can’t repair the damage fast enough and dies.
Starving Cells of Building Blocks
A second class of drugs, called antimetabolites, takes a subtler approach. These molecules are designed to look almost identical to the natural building blocks cells use to construct new DNA and RNA. The cell’s machinery picks them up and tries to use them, like fitting the wrong puzzle piece into a slot. The result is faulty DNA that can’t function. Some antimetabolites block the enzymes responsible for producing those building blocks in the first place, cutting off the supply chain entirely.
These drugs are particularly effective during the phase of the cell cycle when DNA is actively being copied. Cells that are dividing quickly, as cancer cells tend to do, spend more time in this vulnerable phase and encounter the drug more often.
Freezing Cell Division Mid-Split
When a cell is ready to physically divide in two, it builds a scaffold of tiny protein tubes called microtubules. These tubes pull the duplicated chromosomes apart so each new cell gets a complete copy. Two families of drugs disrupt this process from opposite directions.
One group, derived from the periwinkle plant, prevents microtubules from assembling properly. The other group, which includes drugs originally isolated from Pacific yew tree bark, locks microtubules in place so they can’t disassemble when the job is done. Either way, the cell gets stuck mid-division, with its chromosomes condensed but unable to separate. After being frozen at this stage, the cell initiates programmed death. Even at very low concentrations, these drugs don’t need to completely destroy the microtubule network. They just need to suppress its normal dynamic behavior enough to stall the process.
How Cancer Cells Actually Die
Regardless of which drug delivers the initial blow, the endgame is usually the same: the cancer cell activates its built-in self-destruct sequence, a process called apoptosis. This isn’t the cell simply falling apart. It’s an organized demolition. The cell detects that its DNA is too damaged to repair, or that division has stalled beyond recovery, and flips a molecular switch.
That switch activates a cascade of proteins that systematically dismantle the cell from the inside. The cell’s contents are packaged into small fragments that neighboring cells can safely clean up, avoiding the inflammation that would come from a messy, uncontrolled death. Chemo drugs can trigger this cascade through multiple routes. Some activate it through internal stress signals originating in the cell’s powerhouses. Others engage receptors on the cell surface. In many cases, both pathways fire simultaneously.
Why Healthy Cells Get Caught Too
Chemotherapy doesn’t distinguish between a cancer cell that’s dividing and a healthy cell that’s dividing. Any tissue in your body with a naturally high turnover rate becomes collateral damage. Hair follicle cells are among the most rapidly dividing cells in the body. Chemo causes extensive cell death in the hair matrix, which is why hair loss is one of the most visible side effects. It also disrupts the pigment-producing cells in hair follicles, which is why hair sometimes grows back a different color or texture after treatment.
The cells lining your digestive tract replace themselves every few days, making them similarly vulnerable. This explains the nausea, mouth sores, and digestive problems that accompany many chemo regimens. Skin cells (keratinocytes) are among the most actively dividing cells in the body and are susceptible to most chemo agents. Immune cells produced in bone marrow also divide rapidly, which is why chemo often causes drops in white blood cell counts that leave patients more prone to infection.
Combining Drugs for Better Results
Oncologists rarely use a single chemo drug in isolation. Combination regimens use drugs that attack different phases of the cell cycle or damage cells through different mechanisms. The logic is straightforward: at any given moment, cancer cells within a tumor are at various stages of division. A drug that works during DNA copying won’t touch a cell that’s currently in the process of splitting, and vice versa. Using multiple drugs simultaneously catches more cells at their vulnerable moments.
Combination therapy also helps outpace resistance. If a cancer cell develops a way to survive one drug, a second drug working through a completely different mechanism can still kill it. In studies of advanced cancers, combination regimens tend to control disease for longer than single drugs alone, though the benefit varies by cancer type and patient factors like age and overall health.
How Cancer Cells Fight Back
Not every cancer cell dies. Some develop resistance to chemotherapy through several strategies. One of the most common involves molecular pumps embedded in the cell membrane. These pumps actively push the drug back out of the cell before it can do damage, essentially lowering the internal dose to a survivable level. Cancer cells can ramp up production of these pumps, sometimes dramatically.
Other cancer cells boost their DNA repair machinery, patching up the damage chemo inflicts faster than it accumulates. Some undergo genetic mutations that alter the very target the drug was designed to hit, rendering it ineffective. Still others change how they process foreign chemicals, breaking down the drug before it reaches its target. This is why cancers that initially shrink with chemo can later stop responding. The treatment killed the vulnerable cells but left behind a population of resistant survivors that then repopulate the tumor.
Systemic vs. Regional Delivery
Most chemotherapy is systemic, meaning it’s injected into a vein and travels through the entire bloodstream. This allows it to reach cancer cells wherever they’ve spread, but it also exposes every organ to the drug. Regional chemotherapy takes a more targeted approach, delivering the drug directly into the artery feeding the tumor. This creates a high drug concentration at the tumor site while keeping levels in the rest of the body relatively low, which can reduce side effects. Regional delivery is only practical for certain tumor locations and types, so systemic treatment remains the standard for most cancers that have spread beyond a single site.